secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001516551-24-000002
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience raises $50.25M in PIPE led by 5AM Ventures; funds obesity Phase 2 trial
--------------------------------------------------------------------------------

- Private placement of 11.8M shares at $2.305 and pre-funded warrants for 9.98M shares at $2.3049.
- Co-led by 5AM Ventures and another life science investor; includes Ally Bridge, Sphera, Altium, Driehaus.
- Net proceeds expected to fund operations into early 2026, including nimacimab Phase 2 obesity trial starting mid-2024.
- Phase 2a SBI-100 OE trial for glaucoma currently enrolling; interim data expected Q1 2024, topline Q2 2024.
- Directors and officers subject to 90-day lock-up; registration rights agreement filed within 60 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000002/0001516551-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000002/skye-20240129.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer